Globe Life Inc. (GL) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is modestly constructive — consensus sits at a reasonable bar, the biggest swing factor is whether the American Income agent count has begun recovering after Q1’s 4% YoY decline, and the Q3 assumption-update tailwind keeps the full-year EPS story intact regardless of the Q2 print.

Heading into Q2 2026, Globe Life’s consensus EPS estimate of ~$3.69 represents a modest ~13% YoY increase versus the $3.27 reported in Q2 2025, a bar that looks achievable given the company’s track record of double-digit operating EPS growth in seven of the last eight quarters. Management’s tone on the Q1 call was notably confident: full-year 2026 EPS guidance was raised to $15.40–$15.90 (midpoint +$0.35 vs. prior), excess cash flow was narrowed toward the upper end of the $600–$700M range, and the dividend was raised 22% — all signals of conviction in the earnings trajectory. Estimate revisions have been essentially flat since last earnings (the 2Q26 consensus has barely moved from ~$3.72 at the post-Q1 baseline to ~$3.69 today), suggesting the street is neither chasing the raised guidance nor fading it, leaving the bar neither stretched nor depressed. The stock has re-rated sharply since last earnings (+22% vs. KIE +10% and SPY +5%), driven almost entirely by multiple expansion rather than estimate revisions, which means the stock is pricing in continued execution and leaves less room for disappointment. The single biggest wildcard is the American Income agent count: management implemented compensation adjustments at the start of Q2 to rebalance incentives toward recruiting, and any evidence of stabilization or early recovery would be a meaningful positive catalyst, while a continued decline would pressure the 2H growth narrative and likely weigh on the stock despite the Q3 assumption-update cushion.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a reasonable but not low bar — the ~$3.69 operating EPS estimate implies continued double-digit YoY growth. The bigger swing factor is the health underwriting margin, where management guided north of 25% for Q2–Q4 vs. the 22.7% reported in Q1, and where United American rate increases are expected to drive meaningful sequential improvement.

Table 1 — Current Quarter Snapshot (Q2 2026)

Sources: Visible Alpha Consensus and Actuals Data (EPS - Diluted - Operating, Underwriting margin - Life/Health - Underwriting%, Net sales - Life/Health - Underwriting). Q1 2026 actuals and Q2 2025 actuals from Visible Alpha. Q2 2026 consensus as of July 21, 2026.

Table 2 — Beat/Miss History: Net Operating EPS (Last 8 Quarters)

Pattern: GL’s EPS beat/miss history is heavily influenced by Q3 assumption updates (large beats in Q3 2024 and Q3 2025); in non-assumption quarters, results have been close to consensus with a slight tendency to miss by 1–5%, suggesting the street consistently sets a slightly optimistic bar on normalized quarters. Source: Visible Alpha Consensus and Actuals Data.

Table 2b — Beat/Miss History: Life Underwriting Margin % (Last 7 Quarters)

Pattern: Life underwriting margin has beaten consensus in every quarter shown, with the largest beats in Q3 assumption-update quarters. In normalized quarters, the beat is modest (10–60 bps), suggesting consensus is a slightly conservative bar on this KPI. Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Management raised FY 2026 EPS guidance meaningfully at Q1 earnings (April 22) and has not issued any subsequent formal guidance revision; the June 29 credit facility refinancing is the only post-earnings corporate event and carries no earnings guidance implications. Tone remains confident, with the Q3 assumption-update range raised and narrowed.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates for Q2 2026 and FY 2026 have been remarkably stable since the Q1 print — the EPS consensus has barely moved, suggesting the street accepted management’s raised guidance at face value without further revision. The gap between consensus and guidance is minimal, leaving little cushion if execution disappoints.

Estimates have been essentially frozen since the Q1 print, tracking guidance almost exactly. The health underwriting margin consensus sitting precisely at the guided floor (>25%) is the key risk point — any Q2 health margin miss would be a negative surprise with no buffer. Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance Since Last Earnings

Key Takeaway: GL has dramatically outperformed both the insurance sector ETF (KIE) and the S&P 500 since Q1 earnings, with virtually all of the gain driven by multiple expansion rather than estimate revisions — the stock re-rated from ~9.7x NTM P/E to ~11.4x, a 17% multiple expansion, while EPS estimates barely moved.

Sector ETF: KIE (SPDR S&P Insurance ETF) — appropriate for GL’s life/supplemental health insurance sub-sector. Source: Yahoo Finance / Stock Price Data.

Performance decomposition: Over the past 3 months, GL’s +22% total return decomposed as approximately +15.5% from multiple expansion (NTM EV/Sales from 2.21x to 2.55x) and only ~6% from earnings estimate revisions — confirming the re-rating is sentiment/multiple driven. Current NTM P/E of 11.4x compares to 9.7x three months ago, still a discount to historical averages but the gap is narrowing. Source: Stock Performance Decomposition data.

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the June 29 credit facility refinancing, which extends GL’s debt maturity profile and expands liquidity — a modest positive for capital flexibility heading into the Bermuda reinsurance ramp in 2027. No earnings-guidance-moving events have occurred since Q1.

• Jul 8, 2026 — Q2 2026 Earnings Date Announced: Globe Life confirmed results will be released after market close on July 22, 2026, with a conference call on July 23 at 11:00 AM ET. Implication: No surprises on timing; market has had ample time to position.
• Jun 29, 2026 — Credit Facility Refinancing (8-K): Globe Life refinanced its revolving credit facility (admin agent changed from BofA to Wells Fargo; maturity extended to June 2031) and expanded its term loan from $250M to $450M (maturity extended to June 2029). Implication: Improves liquidity runway and financial flexibility; no impact on 2026 EPS guidance, but supports the Bermuda reinsurance initiative and potential capital deployment in 2027+.
• May 4, 2026 — Annual Meeting (8-K): Shareholders approved executive compensation and incentive plan; directors elected. Implication: Routine governance event; no operational read-through.
• Apr 22–23, 2026 — Q1 2026 Earnings (Last Earnings): FY 2026 EPS guidance raised to $15.40–$15.90 (midpoint +$0.35); excess cash flow narrowed to $650M–$700M; share repurchase range raised to $560M–$610M; dividend raised 22%. American Income agent count -4% YoY flagged as a near-term challenge; compensation adjustments implemented at start of Q2. Bermuda reciprocal jurisdiction filing expected in Q2 with update on next call. Implication: The Q2 call will be the first opportunity to assess whether the AIL agent count fix is working and to get a Bermuda update — both are key catalysts.
• Apr 22–23, 2026 — United American Medicare Supplement Tailwind: Management guided ~$65M of additional premium from approved rate increases on individual Medicare supplement policies, primarily in Q2–Q4 2026. Implication: This is a direct Q2 health margin tailwind; if UA margin reaches the guided ~10% in Q2–Q4, health underwriting margin should recover from Q1’s 22.7% to >25% as guided.
• Apr 22–23, 2026 — AI Strategy Update: Management introduced AI as a meaningful tailwind for administrative expense ratios, agent onboarding/retention, lead generation, and underwriting. Implication: Not a near-term Q2 catalyst, but watch for any quantification of AI-driven expense savings in the Q2 call.

7. Peer Commentary — Current-Quarter Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from AFL (June 9) and MET (June 10) at the Morgan Stanley U.S. Financials Conference provides constructive read-throughs for GL’s Q2 2026 print: mortality trends remain favorable, supplemental health underwriting discipline is holding, and the macro backdrop (low unemployment, stable credit) is supportive of GL’s lower-middle-income policyholder base. The main watch item is lapse rates, where AFL flagged elevated lapsation of younger policies in Q1 — a potential read-through to GL’s AIL lapse experience.

Note: Only commentary from the last 60 days (May 21 – July 21, 2026) that addresses Q2 2026 current-quarter conditions or forward-looking trends is included below. Q1 2025 result recaps and prior-quarter retrospectives are excluded.

Aflac (AFL) — Morgan Stanley U.S. Financials Conference, June 9, 2026

• Mortality / Claims (U.S. Supplemental Health): AFL management stated they are “off to a good start for the year” on the U.S. benefit ratio and are “sticking with guidance of 48%–52%” for FY 2026. They noted Q1 had a “pretty low benefit ratio on LTD” which can be “lumpy,” implying some normalization in Q2 is expected but not alarming. → GL Read-Through: Favorable — AFL’s confidence in its full-year benefit ratio guidance suggests the supplemental health claims environment remains benign heading into Q2, consistent with GL’s guided >25% health underwriting margin.
• Lapse Rates (Japan, but relevant to U.S. lower-income dynamics): AFL flagged “elevated lapsation, especially of younger policies where the reserve has not built up enough over time” in Q1, characterizing it as “just a timing on business mix” with no full-year impact. → GL Read-Through: Mixed — GL management similarly characterized AIL’s elevated Q1 lapse rates as a “fluctuation.” AFL’s similar experience and dismissal of it as transient provides some comfort that the lapse pressure is industry-wide and not GL-specific, though it bears watching in Q2.
• AI in Claims Processing: AFL highlighted automating 70% of U.S. claims with AI, targeting payment in under 24–48 hours. → GL Read-Through: Directionally positive for GL’s own AI initiative — validates the industry trend and suggests GL’s administrative expense ratio improvement thesis (guided ~7.3% of premium for FY 2026) is achievable.
• Distribution / Sales: AFL noted competitors are “competing on price” and “highly recruiting some of our agency force,” but AFL is maintaining underwriting discipline. → GL Read-Through: Neutral to slightly negative — competitive recruiting pressure in the agency channel is an industry-wide dynamic that could exacerbate GL’s AIL agent retention challenge in Q2.
• Capital Return: AFL confirmed “significant capital capacity” with underlying cash flow generation of ~$2.5B–$3B annually, continuing to increase dividends and repurchase shares. → GL Read-Through: Positive sector read — confirms the life insurance sector’s strong capital generation capacity, consistent with GL’s own $650M–$700M excess cash flow guidance.

MetLife (MET) — Morgan Stanley U.S. Financials Conference, June 10, 2026

• Macroeconomic Backdrop (Q2 2026 conditions): MET CFO John McCallion described the Q2 environment as a “constructive backdrop”: unemployment remains low, inflation is “manageable,” wage growth is keeping pace, real estate is in a “U-shaped recovery,” and credit is “stable broadly speaking.” → GL Read-Through: Positive — GL’s lower-middle-income policyholder base is most sensitive to employment and wage trends. Low unemployment and manageable inflation reduce lapse risk and support premium persistency, directly relevant to GL’s AIL and Liberty National books.
• Mortality (Group Benefits, Q2 2026 outlook): MET observed “favorability in mortality” in Q1 2026 with the benefit ratio “well below” expectations, and expects this favorable trend to “continue throughout the year.” → GL Read-Through: Positive — Favorable mortality trends at MET are consistent with GL’s own Q1 experience (life policy obligations as % of premium declined from 36.3% to 35.4%) and support GL’s guided ~41% life underwriting margin for Q2 and the elevated Q3 assumption-update range of $70M–$110M.
• Supplemental / Nonmedical Health Benefit Ratio: MET noted its nonmedical health benefit ratio was “towards the top end” of the 70%–75% range in Q1, with higher dental utilization and “a little bit of higher severity on disability.” MET was uncertain whether improvement would come in Q2 or be a first-half/second-half dynamic. → GL Read-Through: Mixed — MET’s dental/disability pressure is not directly comparable to GL’s Medicare Supplement and supplemental life/health products, but elevated health utilization at a large peer is a mild caution flag for GL’s health underwriting margin recovery. The consensus sitting exactly at the guided floor (25.0%) leaves no room for error.
• Variable Investment Income (VII) — Q2 2026 Pressure: MET flagged that “given the way Q1 closed, we could see a little more pressure going into Q2” on VII (which ran above the ~$400M quarterly run rate at $500M+ in Q1). → GL Read-Through: Neutral — GL’s investment income is primarily fixed-maturity driven (97% investment grade, 5.32% earned yield in Q1) with minimal VII exposure, so MET’s VII pressure is not a meaningful read-through for GL’s net investment income line.
• Technology / AI Momentum: MET highlighted auto-adjudicating claims “9x” what it used to and processing “4x the amount of RFPs” in the same time, with AI viewed as a “growth opportunity” and expense ratio reduction driver. → GL Read-Through: Positive — Validates GL’s AI strategy narrative introduced on the Q1 call; industry-wide AI adoption in claims and distribution supports GL’s long-term administrative expense ratio improvement thesis.
• Capital / Free Cash Flow: MET maintained its 65%–75% free cash flow conversion target and guided share repurchases “generally in line with 2025.” → GL Read-Through: Positive sector read — strong capital generation across the life insurance sector supports GL’s own elevated buyback guidance ($560M–$610M for FY 2026).

Summary Read-Through Table:

8. Insider Transaction Activity

Key Takeaway: All post-Q1 insider activity consists exclusively of open-market sales — no open-market buys — across multiple senior executives including both Co-CEOs, the CFO, and the Chief Strategy Officer. While the volume is notable, the sales occurred as the stock rallied sharply (+22% since Q1 earnings), and none are flagged as 10b5-1 planned sales in the data, suggesting discretionary selling into strength. This is a mild negative signal but not alarming given the stock’s significant re-rating.

Observation: The breadth of selling — both Co-CEOs, the CFO, the CSO, the CAO, the Chief Talent Officer, the Chief Accounting Officer, and a Director all sold within the same 10-week window — is notable. None of the transactions are flagged as 10b5-1 pre-planned sales, suggesting discretionary selling into the stock’s sharp post-earnings rally. The absence of any open-market buys is a mild negative signal, though the sales are consistent with normal post-earnings window opening and profit-taking after a 22% run. Source: SEC Form 4 Filings Database.

Appendix — Key Risks to Watch

• American Income Agent Count (Q2 data): The single most important data point on the Q2 call. Management guided low single-digit growth for FY 2026 after implementing compensation adjustments at the start of Q2. Any continued YoY decline would pressure the 2H sales growth narrative and likely weigh on the stock despite the Q3 assumption-update cushion.
• Health Underwriting Margin Recovery: Consensus sits exactly at the guided floor of >25% for Q2. United American rate increases (~$65M in 2026, primarily Q2–Q4) are the key driver. If UA margin does not reach the guided ~10% in Q2–Q4, the health margin will disappoint.
• Bermuda Reinsurance Update: Management promised a Q2 call update on the reciprocal jurisdiction filing. Any delay or complication would be a negative surprise; a clean update confirming the filing and timeline to the $200M annual benefit (expected from 2027) would be a positive catalyst.
• Lapse Rate Normalization: AIL Q1 lapse rates were elevated; management characterized it as a fluctuation. If Q2 data shows continued elevation, it would challenge the “transient” characterization and raise concerns about policyholder affordability in the current macro environment.
• Multiple Compression Risk: The stock has re-rated from ~9.7x to ~11.4x NTM P/E since Q1 earnings, driven almost entirely by multiple expansion. Any earnings miss or guidance cut would likely result in both an EPS and multiple hit, amplifying downside.
• Insider Selling Overhang: Broad-based discretionary selling by senior management into the rally (16 transactions, ~$24M+ in aggregate) could continue to create a technical overhang if the stock continues to appreciate.